

## Tracleer, bosentan

## **Prior Authorization Request**

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-866-814-5506**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do not call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name:							
Patient's ID:			Patient's Date of Birth:				
Phy	ysician's Name:		NPI#:				
Physician Office Telephone:		<del></del>	Physician Office Fax:				
1.	What drug is being prescribed? ☐ Tracleer 32 mg ☐ bosentan 62.5 mg		ng ☐ Tracleer 125 mg				
2.	What is the diagnosis?  ☐ Pulmonary arterial hypertension (PAH) (includes Eisenmenger's syndrome) ☐ Other						
3.	What is the ICD-10 code?						
Con	nplete the following questions i	if Tracleer is being	g prescribed. If bosentan is being prescribed, skip to #11.				
4.	Is the product being requested for the treatment of pulmonary arterial hypertension (PAH) WHO Group 1? ☐ Yes ☐ No If No, skip to #11						
5.	The preferred products for your patient's health plan are ambrisentan, bosentan, and Opsumit. Can the patient's treatment be switched to a preferred product? If switched to ambrisentan or Opsumit, please call 1-866-814-5506 to have the updated form faxed to your office OR you may complete the PA electronically (ePA). You may sign up online via CoverMyMeds at: www.covermymeds.com/epa/caremark/ or call 1-866-452-5017.  Yes - ambrisentan  Yes - bosentan, fax a new prescription to the pharmacy and skip to #11.  Yes - Opsumit  No - Continue request for Tracleer						
6.	Does the patient have a documented intolerable adverse event to the preferred product bosentan? <i>ACTION REQUIRED: If 'Yes', attach supporting chart note(s).</i> $\square$ Yes $\square$ No						
7.	Was the documented intolerable adverse event an expected adverse event attributed to the active ingredient as described in the prescribing information? <i>ACTION REQUIRED: If 'No', attach supporting chart note(s)</i> . $\square$ Yes $\square$ No						
8.	Is the request for a pediatric pa	tient? 🗆 Yes 🗖	No If No, skip to #10				

Send completed form to: Case Review Unit, CVS Caremark Prior Authorization Fax: 1-866-249-6155

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Tracleer [bosentan] ACSF SGM - 5/2023.

9.	Does the patient require the 32 mg tablets for oral suspension? If Yes, skip to #11 ☐ Yes ☐ No						
10.	Does the patient have a documented inadequate response, intolerable adverse event, or contraindication to treatment with any of the preferred products, ambrisentan and Opsumit? <i>ACTION REQUIRED: If 'Yes', attach supporting chart note(s)</i> .						
	□ bosentan: □ ambrisentan: □ Opsumit:	☐ Intolerable adverse event☐ Intolerable adverse event☐ Intolerable adverse event☐ Intolerable adverse event	☐ Inadequate response	e 🗖 Contraindication			
11.	Is the requested medication prescribed by or in consultation with a pulmonologist or cardiologist? ☐ Yes ☐ No						
12.	Is the patient currently receiving treatment with the requested medication?   Yes No If No, skip to #15						
13.	Is the patient currently receiving the requested medication through a paid pharmacy or medical benefit? ☐ Yes ☐ No ☐ Unknown If No or Unknown, skip to #15						
14.	Is the patient experiencing a benefit from therapy with the requested medication as evidenced by disease stability or disease improvement? $\square$ Yes $\square$ No <i>No further questions</i> .						
15.	<ul> <li>What is the World Health Organization (WHO) classification of pulmonary hypertension?</li> <li>□ WHO Group 1 (Pulmonary arterial hypertension)</li> <li>□ WHO Group 2 (Pulmonary hypertension owing to left heart disease)</li> <li>□ WHO Group 3 (Pulmonary hypertension owing to lung disease and/or hypoxia)</li> <li>□ WHO Group 4 (Chronic thromboembolic pulmonary hypertension)</li> <li>□ WHO Group 5 (Pulmonary hypertension with unclear multifactorial mechanisms)</li> </ul>						
16.	Has the diagnosis been confirmed by right heart catheterization? ☐ Yes ☐ No If No, skip to #20						
17.	. What is the pretreatment mean pulmonary arterial pressure (mPAP) at rest? mmHg						
18.	What is the pretreatment pulmonary capillary wedge pressure (PCWP)? mmHg						
19.	What is the pretreatment pulmonary vascular resistance (PVR)? Wood units No further questions.						
20.	Is the patient an infant less than one year of age?   Yes   No						
21.	Has Doppler echocardiogram been performed to confirm the diagnosis? ☐ Yes ☐ No						
	test that this information is ormation is ormation is available for rev						
X_	scriber or Authorized Sign	aturo	Dato (	mm/dd/vv)			
	SOLING VI MULLIVITAGU SIULI	arui C	Date II				